<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081873</url>
  </required_header>
  <id_info>
    <org_study_id>PMOS-BELG-04-001</org_study_id>
    <nct_id>NCT01081873</nct_id>
  </id_info>
  <brief_title>Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer</brief_title>
  <official_title>A Post-Marketing Observational Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatment of Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      Document treatment patterns and evaluate LUCRIN / LUCRIN-TRIDEPOTÂ® (Leuprolide) and
      alternative therapeutic approaches to the treatment of advanced prostate cancer during normal
      clinical practice and in accordance with the terms of the Belgian marketing authorization and
      reimbursement conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness Parameter for Staging of Prostate Cancer: Metastases at Each Visit</measure>
    <time_frame>time 0 (Baseline), month 3, and every 3 months until disease progression or up to 24 months, whichever came first</time_frame>
    <description>The number of participants with metastases that are absent, local tumor, single metastases, multiple metastases in 1 organ, and multiple metastases in multiple organs at each visit is summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness Parameter for Screening or Recurrence of Prostate Cancer: Mean Prostate-specific Antigen (PSA) at Each Visit</measure>
    <time_frame>time 0 (Baseline), month 3, and every 3 months until disease progression or up to 24 months, whichever came first</time_frame>
    <description>The mean PSA in ng/mL to screen and assess for the recurrence of prostate cancer at each visit is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness Parameter: the Number of Participants With a Complete or Partial Response, Stable Disease, or Progressive Disease Following Treatment at Each Visit</measure>
    <time_frame>month 3, and every 3 months until disease progression or up to 24 months, whichever came first</time_frame>
    <description>Response to treatment is summarized by the number of participants at each visit with a complete or partial response, stable disease, or progressive disease. Disease status determination was not predefined, but was based on the judgement of each Investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness Parameter for Prognosis: the Number of Participants With a Survival Prognosis of &gt; 10 Years, 5 - 10 Years, 1 - 5 Years, 6 - 12 Months, and &lt; 6 Months</measure>
    <time_frame>time 0 (Baseline), month 3, and every 3 months thereafter until disease progression or up to 24 months, whichever came first</time_frame>
    <description>The prognosis for participants is summarized for each visit by the number of participants at each visit with a survival prognosis of 10 years, 5 - 10 years, 1 - 5 years, 6 - 12 months, and &lt; 6 months. Methods for determining survival prognosis were not prespecified, but were based on the judgement of each Investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment Patterns for Prostate Cancer Treatments: Number of Participants at Each Visit Who Took Lucrin/Lucrin Tridepot, Luteinizing Hormone-releasing Hormone (LHRH) Agonists, Anti-androgens, or Other Drug Treatments, or Who Had Surgery or Radiotherapy.</measure>
    <time_frame>time 0 (Baseline), month 3, and every 3 months until disease progression or up to 24 months, whichever came first</time_frame>
    <description>Prostate cancer treatment for all participants is summarized by the number of participants at each visit who took any Lucrin/Lucrin Tridepot, LHRH agonist, anti-androgens, or other drug treatments, or who had any type of surgery or radiotherapy (external radiation or brachytherapy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Parameter: Number of Participants Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline to disease progression or 24 months, whichever came first</time_frame>
    <description>The number of participants experiencing a serious adverse event during the course of the study is summarized. See the Reported Adverse Event section for details.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological Data: Mean Weight</measure>
    <time_frame>at time 0 (Baseline)</time_frame>
    <description>The mean weight of all participants at baseline is provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological Data: Mean Age</measure>
    <time_frame>at time 0 (Baseline)</time_frame>
    <description>The mean age of all participants at baseline is provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological Data: Race</measure>
    <time_frame>at time 0 (Baseline)</time_frame>
    <description>The number of participants by race at baseline is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological Data: Tumor Staging - Among Participants With a Positive Biopsy, the Number of Participants With Adenocarcinoma Tissue or Other Tissues Recorded for the Positive Biopsy.</measure>
    <time_frame>at time 0 (Baseline)</time_frame>
    <description>Among those participants with a positive biopsy at baseline, the number of participants with adenocarcinoma tissue or other tissue type is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological Data: PSA at Baseline</measure>
    <time_frame>at time 0 (Baseline)</time_frame>
    <description>The median, minimum, and maximum PSA values in ng/mL at baseline are provided. The mean PSA at baseline is reported in the Primary Outcome Measure section above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological Data: Tumor Staging (Positive or Negative) Via a Rectal Examination, Prostate Biopsy, Echograph, or Magnetic Resonance Imaging (MRI) Test.</measure>
    <time_frame>at time 0 (Baseline)</time_frame>
    <description>The number of participants at baseline who were positive or negative for tumors via a rectal examination, prostate biopsy, echograph of the hyperechogenic zones, or MRI are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological Data: the Number of Participants With Tumor Stages T0, T1, T2, T3, and T4.</measure>
    <time_frame>at time 0 (Baseline)</time_frame>
    <description>The number of participants with tumor stages T0, T1, T2, T3, and T4 as reported by the physician or pathologist is summarized. T0: no evidence of primary tumor. T1: histologic tumor confined to prostate; clinically unapparent tumor, undetectable by digital rectal examination or by ultrasound. T2: tumor is confined to prostrate and can be detected by digital rectal examination. T3: tumor extends through the prostate capsule but has not spread to other organs. T4: tumor has invaded adjacent structures/organs other than seminal vesicles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological Data: Node Staging - the Number of Participants With a Positive or Negative Computerized Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) Test</measure>
    <time_frame>at time 0 (Baseline)</time_frame>
    <description>In this case, a CT or MRI is considered positive when lymph nodes are detectable. A CT or MRI is considered negative when lymph nodes are not detectable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological Data: Node Staging - the Number of Participants With a N0 or N1 Stage at Baseline.</measure>
    <time_frame>at time 0 (Baseline)</time_frame>
    <description>N0: tumor cells absent from regional lymph nodes. N1: regional lymph node metastasis present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological Data: Bone Scan at Baseline</measure>
    <time_frame>at time 0 (Baseline)</time_frame>
    <description>The number of participants at baseline with a positive or negative bone scan was summarized. Determination of bone scan status was based on the interpretation of the Investigator or radiologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiological Data: Metastasis Staging (M0 or M1) at Baseline</measure>
    <time_frame>at time 0 (Baseline)</time_frame>
    <description>The number of participants at baseline reported to be in metastasis stage M0 or M1 is summarized. M0: no distant metastasis. M1: metastasis to distant organs beyond regional lymph nodes.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2717</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>Advanced prostate cancer participants</arm_group_label>
    <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment within local reimbursement guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide (Lucrin/Lucrin-Tri-depot)</intervention_name>
    <description>Subcutaneous or intramuscular administration for all participants</description>
    <arm_group_label>Advanced prostate cancer participants</arm_group_label>
    <other_name>Lucrin</other_name>
    <other_name>Lucrin-Tri-depot</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Urologists
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with advanced prostate cancer who have been prescribed Lucrin/
             Lucrin-Tri-depot or any other treatment with local reimbursement guidelines; Patients
             willing to consent to data being collected and provided to Abbott Laboratories.

        Exclusion Criteria:

          -  Contraindications according to the Summary of Product Characteristics (SPC).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simonne Lens</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31196</name>
      <address>
        <city>Aartselaar</city>
        <zip>B-2630</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31237</name>
      <address>
        <city>Afsnee</city>
        <zip>B-9051</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31121</name>
      <address>
        <city>Alken</city>
        <zip>B-3570</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31170</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31194</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4872</name>
      <address>
        <city>Antwerp</city>
        <zip>B-2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31186</name>
      <address>
        <city>Antwerp</city>
        <zip>B-2050</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31141</name>
      <address>
        <city>Arlon</city>
        <zip>B-6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31199</name>
      <address>
        <city>Arlon</city>
        <zip>B-6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31247</name>
      <address>
        <city>Ath</city>
        <zip>B-7804</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31190</name>
      <address>
        <city>Baulers</city>
        <zip>B-1401</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31210</name>
      <address>
        <city>Beerse</city>
        <zip>B-2340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31171</name>
      <address>
        <city>Berchem</city>
        <zip>B-2600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31137</name>
      <address>
        <city>Berlaar</city>
        <zip>B-2590</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31204</name>
      <address>
        <city>Beveren</city>
        <zip>B-8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31184</name>
      <address>
        <city>Boutersem</city>
        <zip>B-3370</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31205</name>
      <address>
        <city>Braine-Le-Chateau</city>
        <zip>B-1440</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31217</name>
      <address>
        <city>Brasschaat</city>
        <zip>B-2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31133</name>
      <address>
        <city>Bruges</city>
        <zip>B-8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31135</name>
      <address>
        <city>Bruges</city>
        <zip>B-8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31134</name>
      <address>
        <city>Brugge</city>
        <zip>B-8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31233</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31252</name>
      <address>
        <city>Brussels</city>
        <zip>B-1160</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31232</name>
      <address>
        <city>Brussels</city>
        <zip>B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31161</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31223</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1030</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31152</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31251</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1081</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31178</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1083</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31236</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31117</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31203</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31200</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1853</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31129</name>
      <address>
        <city>Court St. Etienne</city>
        <zip>B-1490</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31244</name>
      <address>
        <city>Cuesmes</city>
        <zip>B-7033</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31208</name>
      <address>
        <city>Damme</city>
        <zip>B-8340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31155</name>
      <address>
        <city>Dendermonde</city>
        <zip>B-9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31197</name>
      <address>
        <city>Dendermonde</city>
        <zip>B-9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31189</name>
      <address>
        <city>Diest</city>
        <zip>B-3290</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31126</name>
      <address>
        <city>Dilbeek</city>
        <zip>B-1700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31116</name>
      <address>
        <city>Dworp</city>
        <zip>B-1653</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31160</name>
      <address>
        <city>Dworp</city>
        <zip>B-1653</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31179</name>
      <address>
        <city>Elingen</city>
        <zip>B-1671</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31249</name>
      <address>
        <city>Embourg</city>
        <zip>B-4053</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31166</name>
      <address>
        <city>Erpent</city>
        <zip>B-5101</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31192</name>
      <address>
        <city>Esneux</city>
        <zip>B-4130</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31188</name>
      <address>
        <city>Falmagne</city>
        <zip>B-5500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31195</name>
      <address>
        <city>Feluy</city>
        <zip>B-7181</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31250</name>
      <address>
        <city>Floreffe</city>
        <zip>B-5150</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31173</name>
      <address>
        <city>Genk-Waterschei</city>
        <zip>B-3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31183</name>
      <address>
        <city>Genk</city>
        <zip>B-3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31228</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 46502</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31132</name>
      <address>
        <city>Gouy-Les-Pietons</city>
        <zip>B-6181</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31124</name>
      <address>
        <city>Halle</city>
        <zip>B-1500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31191</name>
      <address>
        <city>Hamme</city>
        <zip>B-9220</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31234</name>
      <address>
        <city>Hasselt</city>
        <zip>B-3510</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31227</name>
      <address>
        <city>Heusy</city>
        <zip>B-4802</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31212</name>
      <address>
        <city>Hofstade</city>
        <zip>B-1981</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31143</name>
      <address>
        <city>Hove</city>
        <zip>B-2540</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31226</name>
      <address>
        <city>Huy</city>
        <zip>B-4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31119</name>
      <address>
        <city>Izegem</city>
        <zip>B-8870</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31181</name>
      <address>
        <city>Izegem</city>
        <zip>B-8870</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31149</name>
      <address>
        <city>Knokke</city>
        <zip>B-8300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31177</name>
      <address>
        <city>Koksijde</city>
        <zip>B-8670</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31253</name>
      <address>
        <city>Kortrijk</city>
        <zip>B-8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31130</name>
      <address>
        <city>Lasne</city>
        <zip>B-1380</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31159</name>
      <address>
        <city>Lennik</city>
        <zip>B-1750</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31123</name>
      <address>
        <city>Leper</city>
        <zip>B-8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31241</name>
      <address>
        <city>Leper</city>
        <zip>B-8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31255</name>
      <address>
        <city>Lesves</city>
        <zip>B-1380</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31259</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31219</name>
      <address>
        <city>Libramont</city>
        <zip>B-6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31128</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31144</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31185</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31207</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31245</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31224</name>
      <address>
        <city>Lier</city>
        <zip>B2400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31243</name>
      <address>
        <city>Lommel</city>
        <zip>B-3920</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31225</name>
      <address>
        <city>Marcinelle</city>
        <zip>B-6001</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31139</name>
      <address>
        <city>Marcq</city>
        <zip>B-7850</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31206</name>
      <address>
        <city>Mol</city>
        <zip>B-2400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31153</name>
      <address>
        <city>Mons</city>
        <zip>B-7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31257</name>
      <address>
        <city>Mons</city>
        <zip>B-7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31140</name>
      <address>
        <city>Mont-sur-Marchienne</city>
        <zip>B-6032</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31222</name>
      <address>
        <city>Mortsel</city>
        <zip>B2640</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31164</name>
      <address>
        <city>Namur</city>
        <zip>B-5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31258</name>
      <address>
        <city>Nivelles</city>
        <zip>B-1400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31218</name>
      <address>
        <city>Oordegem</city>
        <zip>B-9340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31214</name>
      <address>
        <city>Oostende</city>
        <zip>B-8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31242</name>
      <address>
        <city>Oostende</city>
        <zip>B-8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31156</name>
      <address>
        <city>Oosterzele</city>
        <zip>B-9860</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31131</name>
      <address>
        <city>Ottignies</city>
        <zip>B-1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31163</name>
      <address>
        <city>Oudenaarde</city>
        <zip>B-9700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31125</name>
      <address>
        <city>Overijse</city>
        <zip>B-3090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31198</name>
      <address>
        <city>Pollinkhove</city>
        <zip>B-8647</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31229</name>
      <address>
        <city>Ragnies</city>
        <zip>B-6532</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31138</name>
      <address>
        <city>Rijmenam</city>
        <zip>B-2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31122</name>
      <address>
        <city>Roeselare</city>
        <zip>B-8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31174</name>
      <address>
        <city>Roeslare</city>
        <zip>B-8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31136</name>
      <address>
        <city>Rotselaar</city>
        <zip>B-3110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31180</name>
      <address>
        <city>Rumbeke</city>
        <zip>B-8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31147</name>
      <address>
        <city>S. Gravenwezel</city>
        <zip>B-2970</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31215</name>
      <address>
        <city>Saint Ghislain</city>
        <zip>B-7330</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31176</name>
      <address>
        <city>Saintes</city>
        <zip>B-1480</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31168</name>
      <address>
        <city>Schilde</city>
        <zip>B-2970</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31220</name>
      <address>
        <city>Schoten</city>
        <zip>B-2900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31238</name>
      <address>
        <city>Schoten</city>
        <zip>B-2900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31142</name>
      <address>
        <city>Seneffe</city>
        <zip>B-7180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31158</name>
      <address>
        <city>Seraing</city>
        <zip>B-4100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31246</name>
      <address>
        <city>Silly</city>
        <zip>B-7830</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31240</name>
      <address>
        <city>Sint Niklaas</city>
        <zip>B-9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31120</name>
      <address>
        <city>Sint Truiden</city>
        <zip>B-3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31230</name>
      <address>
        <city>Sint-Genesius-Rode</city>
        <zip>B-1640</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31213</name>
      <address>
        <city>Sirault</city>
        <zip>B-7332</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31150</name>
      <address>
        <city>St Denis</city>
        <zip>B-7034</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31157</name>
      <address>
        <city>St. Truiden</city>
        <zip>B-3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31182</name>
      <address>
        <city>Tielt</city>
        <zip>B-8700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31248</name>
      <address>
        <city>Tilff</city>
        <zip>B-4130</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31151</name>
      <address>
        <city>Tournai</city>
        <zip>B-7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31146</name>
      <address>
        <city>Tremelo</city>
        <zip>B-3120</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31254</name>
      <address>
        <city>Uccle</city>
        <zip>B-1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31256</name>
      <address>
        <city>Uccle</city>
        <zip>B-1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31165</name>
      <address>
        <city>Veerle</city>
        <zip>B-2431</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31193</name>
      <address>
        <city>Villers-Saint-Simeon</city>
        <zip>B-4453</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31175</name>
      <address>
        <city>Wanze</city>
        <zip>B-4520</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31145</name>
      <address>
        <city>Waregem</city>
        <zip>B-8790</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31202</name>
      <address>
        <city>Wilrijk</city>
        <zip>B-2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31201</name>
      <address>
        <city>Woluwe St Pierre</city>
        <zip>B-1150</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31216</name>
      <address>
        <city>Xhendelesse</city>
        <zip>B-4652</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31221</name>
      <address>
        <city>Bascharage</city>
        <zip>L-4918</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31172</name>
      <address>
        <city>Esch-sur-Alzette</city>
        <zip>L-4243</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31162</name>
      <address>
        <city>Ettelbruck</city>
        <zip>L-9002</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 31231</name>
      <address>
        <city>Luxembourg</city>
        <zip>L-2540</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <results_first_submitted>December 22, 2011</results_first_submitted>
  <results_first_submitted_qc>February 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2012</results_first_posted>
  <last_update_submitted>October 26, 2012</last_update_submitted>
  <last_update_submitted_qc>October 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multicenter study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Advanced Prostate Cancer Participants</title>
          <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2714">3 patients were excluded from this and all analyses due to no available data from Baseline.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2416"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of prostate cancer</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Advanced Prostate Cancer Participants</title>
          <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses. Age was available for 2,691 patients only; age was missing for 23 patients who were thus not included in the age results.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2714"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.18" lower_limit="46.3" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.39" spread="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness Parameter for Staging of Prostate Cancer: Metastases at Each Visit</title>
        <description>The number of participants with metastases that are absent, local tumor, single metastases, multiple metastases in 1 organ, and multiple metastases in multiple organs at each visit is summarized.</description>
        <time_frame>time 0 (Baseline), month 3, and every 3 months until disease progression or up to 24 months, whichever came first</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants at Baseline</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Advanced Prostate Cancer Participants at Month 3</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 3.</description>
          </group>
          <group group_id="O3">
            <title>Advanced Prostate Cancer Participants at Month 6</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 6.</description>
          </group>
          <group group_id="O4">
            <title>Advanced Prostate Cancer Participants at Month 9</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had had a value recorded at Month 9.</description>
          </group>
          <group group_id="O5">
            <title>Advanced Prostate Cancer Participants at Month 12</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 12</description>
          </group>
          <group group_id="O6">
            <title>Advanced Prostate Cancer Participants at Month 15</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 15.</description>
          </group>
          <group group_id="O7">
            <title>Advanced Prostate Cancer Participants at Month 18</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 18.</description>
          </group>
          <group group_id="O8">
            <title>Advanced Prostate Cancer Participants at Month 21</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 21.</description>
          </group>
          <group group_id="O9">
            <title>Advanced Prostate Cancer Participants at Month 24</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 24.</description>
          </group>
          <group group_id="O10">
            <title>Advanced Prostate Cancer Participants - Last Available Record</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had any final value recorded.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness Parameter for Staging of Prostate Cancer: Metastases at Each Visit</title>
          <description>The number of participants with metastases that are absent, local tumor, single metastases, multiple metastases in 1 organ, and multiple metastases in multiple organs at each visit is summarized.</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data at each visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1262"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="109"/>
                <count group_id="O6" value="54"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="52"/>
                <count group_id="O9" value="310"/>
                <count group_id="O10" value="1411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="782"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="74"/>
                    <measurement group_id="O6" value="33"/>
                    <measurement group_id="O7" value="44"/>
                    <measurement group_id="O8" value="29"/>
                    <measurement group_id="O9" value="188"/>
                    <measurement group_id="O10" value="870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="15"/>
                    <measurement group_id="O10" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple metastases in 1 organ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="63"/>
                    <measurement group_id="O10" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple metastases in multiple organs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="34"/>
                    <measurement group_id="O10" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness Parameter for Screening or Recurrence of Prostate Cancer: Mean Prostate-specific Antigen (PSA) at Each Visit</title>
        <description>The mean PSA in ng/mL to screen and assess for the recurrence of prostate cancer at each visit is presented.</description>
        <time_frame>time 0 (Baseline), month 3, and every 3 months until disease progression or up to 24 months, whichever came first</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants at Baseline</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Advanced Prostate Cancer Participants at Month 3</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 3.</description>
          </group>
          <group group_id="O3">
            <title>Advanced Prostate Cancer Participants at Month 6</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 6.</description>
          </group>
          <group group_id="O4">
            <title>Advanced Prostate Cancer Participants at Month 9</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had had a value recorded at Month 9.</description>
          </group>
          <group group_id="O5">
            <title>Advanced Prostate Cancer Participants at Month 12</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 12</description>
          </group>
          <group group_id="O6">
            <title>Advanced Prostate Cancer Participants at Month 15</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 15.</description>
          </group>
          <group group_id="O7">
            <title>Advanced Prostate Cancer Participants at Month 18</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 18.</description>
          </group>
          <group group_id="O8">
            <title>Advanced Prostate Cancer Participants at Month 21</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 21.</description>
          </group>
          <group group_id="O9">
            <title>Advanced Prostate Cancer Participants at Month 24</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 24.</description>
          </group>
          <group group_id="O10">
            <title>Advanced Prostate Cancer Participants - Last Available Record</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had any final value recorded.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness Parameter for Screening or Recurrence of Prostate Cancer: Mean Prostate-specific Antigen (PSA) at Each Visit</title>
          <description>The mean PSA in ng/mL to screen and assess for the recurrence of prostate cancer at each visit is presented.</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data at each visit.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2532"/>
                <count group_id="O2" value="944"/>
                <count group_id="O3" value="787"/>
                <count group_id="O4" value="595"/>
                <count group_id="O5" value="978"/>
                <count group_id="O6" value="493"/>
                <count group_id="O7" value="612"/>
                <count group_id="O8" value="401"/>
                <count group_id="O9" value="1661"/>
                <count group_id="O10" value="2595"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.16" spread="282.64"/>
                    <measurement group_id="O2" value="12.95" spread="88.03"/>
                    <measurement group_id="O3" value="6.23" spread="34.27"/>
                    <measurement group_id="O4" value="8.01" spread="43.28"/>
                    <measurement group_id="O5" value="8.41" spread="52.84"/>
                    <measurement group_id="O6" value="8.88" spread="44.66"/>
                    <measurement group_id="O7" value="9.57" spread="57.42"/>
                    <measurement group_id="O8" value="23.02" spread="141.92"/>
                    <measurement group_id="O9" value="15.29" spread="129.06"/>
                    <measurement group_id="O10" value="30.32" spread="183.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness Parameter: the Number of Participants With a Complete or Partial Response, Stable Disease, or Progressive Disease Following Treatment at Each Visit</title>
        <description>Response to treatment is summarized by the number of participants at each visit with a complete or partial response, stable disease, or progressive disease. Disease status determination was not predefined, but was based on the judgement of each Investigator.</description>
        <time_frame>month 3, and every 3 months until disease progression or up to 24 months, whichever came first</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants at Month 3</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 3.</description>
          </group>
          <group group_id="O2">
            <title>Advanced Prostate Cancer Participants at Month 6</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 6.</description>
          </group>
          <group group_id="O3">
            <title>Advanced Prostate Cancer Participants at Month 9</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had had a value recorded at Month 9.</description>
          </group>
          <group group_id="O4">
            <title>Advanced Prostate Cancer Participants at Month 12</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 12</description>
          </group>
          <group group_id="O5">
            <title>Advanced Prostate Cancer Participants at Month 15</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 15.</description>
          </group>
          <group group_id="O6">
            <title>Advanced Prostate Cancer Participants at Month 18</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 18.</description>
          </group>
          <group group_id="O7">
            <title>Advanced Prostate Cancer Participants at Month 21</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 21.</description>
          </group>
          <group group_id="O8">
            <title>Advanced Prostate Cancer Participants at Month 24</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 24.</description>
          </group>
          <group group_id="O9">
            <title>Advanced Prostate Cancer Participants - Last Available Record</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had any final value recorded.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness Parameter: the Number of Participants With a Complete or Partial Response, Stable Disease, or Progressive Disease Following Treatment at Each Visit</title>
          <description>Response to treatment is summarized by the number of participants at each visit with a complete or partial response, stable disease, or progressive disease. Disease status determination was not predefined, but was based on the judgement of each Investigator.</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data at each visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1038"/>
                <count group_id="O2" value="853"/>
                <count group_id="O3" value="670"/>
                <count group_id="O4" value="1031"/>
                <count group_id="O5" value="565"/>
                <count group_id="O6" value="679"/>
                <count group_id="O7" value="475"/>
                <count group_id="O8" value="1764"/>
                <count group_id="O9" value="2210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525"/>
                    <measurement group_id="O2" value="496"/>
                    <measurement group_id="O3" value="402"/>
                    <measurement group_id="O4" value="668"/>
                    <measurement group_id="O5" value="347"/>
                    <measurement group_id="O6" value="401"/>
                    <measurement group_id="O7" value="276"/>
                    <measurement group_id="O8" value="1181"/>
                    <measurement group_id="O9" value="1420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379"/>
                    <measurement group_id="O2" value="231"/>
                    <measurement group_id="O3" value="139"/>
                    <measurement group_id="O4" value="181"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="98"/>
                    <measurement group_id="O7" value="59"/>
                    <measurement group_id="O8" value="199"/>
                    <measurement group_id="O9" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="69"/>
                    <measurement group_id="O6" value="102"/>
                    <measurement group_id="O7" value="73"/>
                    <measurement group_id="O8" value="200"/>
                    <measurement group_id="O9" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="52"/>
                    <measurement group_id="O6" value="78"/>
                    <measurement group_id="O7" value="67"/>
                    <measurement group_id="O8" value="184"/>
                    <measurement group_id="O9" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness Parameter for Prognosis: the Number of Participants With a Survival Prognosis of &gt; 10 Years, 5 - 10 Years, 1 - 5 Years, 6 - 12 Months, and &lt; 6 Months</title>
        <description>The prognosis for participants is summarized for each visit by the number of participants at each visit with a survival prognosis of 10 years, 5 - 10 years, 1 - 5 years, 6 - 12 months, and &lt; 6 months. Methods for determining survival prognosis were not prespecified, but were based on the judgement of each Investigator.</description>
        <time_frame>time 0 (Baseline), month 3, and every 3 months thereafter until disease progression or up to 24 months, whichever came first</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants at Baseline</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Advanced Prostate Cancer Participants at Month 3</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 3.</description>
          </group>
          <group group_id="O3">
            <title>Advanced Prostate Cancer Participants at Month 6</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 6.</description>
          </group>
          <group group_id="O4">
            <title>Advanced Prostate Cancer Participants at Month 9</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had had a value recorded at Month 9.</description>
          </group>
          <group group_id="O5">
            <title>Advanced Prostate Cancer Participants at Month 12</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 12</description>
          </group>
          <group group_id="O6">
            <title>Advanced Prostate Cancer Participants at Month 15</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 15.</description>
          </group>
          <group group_id="O7">
            <title>Advanced Prostate Cancer Participants at Month 18</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 18.</description>
          </group>
          <group group_id="O8">
            <title>Advanced Prostate Cancer Participants at Month 21</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 21.</description>
          </group>
          <group group_id="O9">
            <title>Advanced Prostate Cancer Participants at Month 24</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 24.</description>
          </group>
          <group group_id="O10">
            <title>Advanced Prostate Cancer Participants - Last Available Record</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had any final value recorded.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness Parameter for Prognosis: the Number of Participants With a Survival Prognosis of &gt; 10 Years, 5 - 10 Years, 1 - 5 Years, 6 - 12 Months, and &lt; 6 Months</title>
          <description>The prognosis for participants is summarized for each visit by the number of participants at each visit with a survival prognosis of 10 years, 5 - 10 years, 1 - 5 years, 6 - 12 months, and &lt; 6 months. Methods for determining survival prognosis were not prespecified, but were based on the judgement of each Investigator.</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data at each visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2128"/>
                <count group_id="O2" value="941"/>
                <count group_id="O3" value="752"/>
                <count group_id="O4" value="604"/>
                <count group_id="O5" value="881"/>
                <count group_id="O6" value="509"/>
                <count group_id="O7" value="593"/>
                <count group_id="O8" value="426"/>
                <count group_id="O9" value="1495"/>
                <count group_id="O10" value="2365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt; 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="91"/>
                    <measurement group_id="O5" value="113"/>
                    <measurement group_id="O6" value="75"/>
                    <measurement group_id="O7" value="82"/>
                    <measurement group_id="O8" value="66"/>
                    <measurement group_id="O9" value="206"/>
                    <measurement group_id="O10" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1041"/>
                    <measurement group_id="O2" value="476"/>
                    <measurement group_id="O3" value="402"/>
                    <measurement group_id="O4" value="320"/>
                    <measurement group_id="O5" value="479"/>
                    <measurement group_id="O6" value="276"/>
                    <measurement group_id="O7" value="309"/>
                    <measurement group_id="O8" value="225"/>
                    <measurement group_id="O9" value="805"/>
                    <measurement group_id="O10" value="1173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 - 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="663"/>
                    <measurement group_id="O2" value="312"/>
                    <measurement group_id="O3" value="237"/>
                    <measurement group_id="O4" value="180"/>
                    <measurement group_id="O5" value="268"/>
                    <measurement group_id="O6" value="140"/>
                    <measurement group_id="O7" value="182"/>
                    <measurement group_id="O8" value="117"/>
                    <measurement group_id="O9" value="420"/>
                    <measurement group_id="O10" value="735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="48"/>
                    <measurement group_id="O10" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment Patterns for Prostate Cancer Treatments: Number of Participants at Each Visit Who Took Lucrin/Lucrin Tridepot, Luteinizing Hormone-releasing Hormone (LHRH) Agonists, Anti-androgens, or Other Drug Treatments, or Who Had Surgery or Radiotherapy.</title>
        <description>Prostate cancer treatment for all participants is summarized by the number of participants at each visit who took any Lucrin/Lucrin Tridepot, LHRH agonist, anti-androgens, or other drug treatments, or who had any type of surgery or radiotherapy (external radiation or brachytherapy).</description>
        <time_frame>time 0 (Baseline), month 3, and every 3 months until disease progression or up to 24 months, whichever came first</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data at each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants at Baseline</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Advanced Prostate Cancer Participants at Month 3</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 3.</description>
          </group>
          <group group_id="O3">
            <title>Advanced Prostate Cancer Participants at Month 6</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 6.</description>
          </group>
          <group group_id="O4">
            <title>Advanced Prostate Cancer Participants at Month 9</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had had a value recorded at Month 9.</description>
          </group>
          <group group_id="O5">
            <title>Advanced Prostate Cancer Participants at Month 12</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 12</description>
          </group>
          <group group_id="O6">
            <title>Advanced Prostate Cancer Participants at Month 15</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 15.</description>
          </group>
          <group group_id="O7">
            <title>Advanced Prostate Cancer Participants at Month 18</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 18.</description>
          </group>
          <group group_id="O8">
            <title>Advanced Prostate Cancer Participants at Month 21</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 21.</description>
          </group>
          <group group_id="O9">
            <title>Advanced Prostate Cancer Participants at Month 24</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a value recorded at Month 24.</description>
          </group>
          <group group_id="O10">
            <title>Advanced Prostate Cancer Participants - Use at Any Visit</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had used any of the treatments at any visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Patterns for Prostate Cancer Treatments: Number of Participants at Each Visit Who Took Lucrin/Lucrin Tridepot, Luteinizing Hormone-releasing Hormone (LHRH) Agonists, Anti-androgens, or Other Drug Treatments, or Who Had Surgery or Radiotherapy.</title>
          <description>Prostate cancer treatment for all participants is summarized by the number of participants at each visit who took any Lucrin/Lucrin Tridepot, LHRH agonist, anti-androgens, or other drug treatments, or who had any type of surgery or radiotherapy (external radiation or brachytherapy).</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data at each visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2714"/>
                <count group_id="O2" value="1134"/>
                <count group_id="O3" value="907"/>
                <count group_id="O4" value="715"/>
                <count group_id="O5" value="1082"/>
                <count group_id="O6" value="611"/>
                <count group_id="O7" value="717"/>
                <count group_id="O8" value="513"/>
                <count group_id="O9" value="1954"/>
                <count group_id="O10" value="2714"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Lucrin or Lucrin Tridepot used at each visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2028"/>
                    <measurement group_id="O2" value="1011"/>
                    <measurement group_id="O3" value="817"/>
                    <measurement group_id="O4" value="640"/>
                    <measurement group_id="O5" value="969"/>
                    <measurement group_id="O6" value="540"/>
                    <measurement group_id="O7" value="629"/>
                    <measurement group_id="O8" value="450"/>
                    <measurement group_id="O9" value="1628"/>
                    <measurement group_id="O10" value="2384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any LHRH agonist treatments used at each visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2034"/>
                    <measurement group_id="O2" value="1015"/>
                    <measurement group_id="O3" value="821"/>
                    <measurement group_id="O4" value="643"/>
                    <measurement group_id="O5" value="973"/>
                    <measurement group_id="O6" value="545"/>
                    <measurement group_id="O7" value="636"/>
                    <measurement group_id="O8" value="452"/>
                    <measurement group_id="O9" value="1635"/>
                    <measurement group_id="O10" value="2392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any anti-androgen treatments used at each visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="841"/>
                    <measurement group_id="O2" value="388"/>
                    <measurement group_id="O3" value="303"/>
                    <measurement group_id="O4" value="243"/>
                    <measurement group_id="O5" value="397"/>
                    <measurement group_id="O6" value="223"/>
                    <measurement group_id="O7" value="261"/>
                    <measurement group_id="O8" value="182"/>
                    <measurement group_id="O9" value="603"/>
                    <measurement group_id="O10" value="1021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other drug treatments used at each visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="23"/>
                    <measurement group_id="O9" value="57"/>
                    <measurement group_id="O10" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any surgery performed any time up to the visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244"/>
                    <measurement group_id="O2" value="145"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="127"/>
                    <measurement group_id="O6" value="92"/>
                    <measurement group_id="O7" value="94"/>
                    <measurement group_id="O8" value="80"/>
                    <measurement group_id="O9" value="192"/>
                    <measurement group_id="O10" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>External radiation performed any time up to visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="73"/>
                    <measurement group_id="O5" value="79"/>
                    <measurement group_id="O6" value="43"/>
                    <measurement group_id="O7" value="56"/>
                    <measurement group_id="O8" value="33"/>
                    <measurement group_id="O9" value="133"/>
                    <measurement group_id="O10" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brachytherapy performed any time up to the visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="21"/>
                    <measurement group_id="O10" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Parameter: Number of Participants Reporting Serious Adverse Events (SAEs)</title>
        <description>The number of participants experiencing a serious adverse event during the course of the study is summarized. See the Reported Adverse Event section for details.</description>
        <time_frame>Baseline to disease progression or 24 months, whichever came first</time_frame>
        <population>Analysis was performed on the full analysis set consisting of all patients for whom at least baseline data were recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Parameter: Number of Participants Reporting Serious Adverse Events (SAEs)</title>
          <description>The number of participants experiencing a serious adverse event during the course of the study is summarized. See the Reported Adverse Event section for details.</description>
          <population>Analysis was performed on the full analysis set consisting of all patients for whom at least baseline data were recorded.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2714"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidemiological Data: Mean Weight</title>
        <description>The mean weight of all participants at baseline is provided.</description>
        <time_frame>at time 0 (Baseline)</time_frame>
        <population>Analysis was performed on the full analysis set consisting of all patients for whom at least baseline data were recorded. Data for age was available for 2,691 patients and for weight for 2,116 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Epidemiological Data: Mean Weight</title>
          <description>The mean weight of all participants at baseline is provided.</description>
          <population>Analysis was performed on the full analysis set consisting of all patients for whom at least baseline data were recorded. Data for age was available for 2,691 patients and for weight for 2,116 patients.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2714"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.36" spread="10.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidemiological Data: Mean Age</title>
        <description>The mean age of all participants at baseline is provided.</description>
        <time_frame>at time 0 (Baseline)</time_frame>
        <population>Analysis was performed on the full analysis set consisting of all patients for whom at least baseline data were recorded. Data for age was available for 2,691 patients and for weight for 2,116 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Epidemiological Data: Mean Age</title>
          <description>The mean age of all participants at baseline is provided.</description>
          <population>Analysis was performed on the full analysis set consisting of all patients for whom at least baseline data were recorded. Data for age was available for 2,691 patients and for weight for 2,116 patients.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2714"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.39" spread="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidemiological Data: Race</title>
        <description>The number of participants by race at baseline is presented.</description>
        <time_frame>at time 0 (Baseline)</time_frame>
        <population>Analysis was performed on the full analysis set consisting of all patients for whom at least baseline data were recorded. Data for race was available for 2,217 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Epidemiological Data: Race</title>
          <description>The number of participants by race at baseline is presented.</description>
          <population>Analysis was performed on the full analysis set consisting of all patients for whom at least baseline data were recorded. Data for race was available for 2,217 patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidemiological Data: Tumor Staging - Among Participants With a Positive Biopsy, the Number of Participants With Adenocarcinoma Tissue or Other Tissues Recorded for the Positive Biopsy.</title>
        <description>Among those participants with a positive biopsy at baseline, the number of participants with adenocarcinoma tissue or other tissue type is summarized.</description>
        <time_frame>at time 0 (Baseline)</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants at Baseline</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines that had a tissue type recorded at Baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>Epidemiological Data: Tumor Staging - Among Participants With a Positive Biopsy, the Number of Participants With Adenocarcinoma Tissue or Other Tissues Recorded for the Positive Biopsy.</title>
          <description>Among those participants with a positive biopsy at baseline, the number of participants with adenocarcinoma tissue or other tissue type is summarized.</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidemiological Data: PSA at Baseline</title>
        <description>The median, minimum, and maximum PSA values in ng/mL at baseline are provided. The mean PSA at baseline is reported in the Primary Outcome Measure section above.</description>
        <time_frame>at time 0 (Baseline)</time_frame>
        <population>Analysis was performed on the full analysis set consisting of all patients for whom at least baseline data were recorded. Data for PSA at baseline was available for 2,532 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Epidemiological Data: PSA at Baseline</title>
          <description>The median, minimum, and maximum PSA values in ng/mL at baseline are provided. The mean PSA at baseline is reported in the Primary Outcome Measure section above.</description>
          <population>Analysis was performed on the full analysis set consisting of all patients for whom at least baseline data were recorded. Data for PSA at baseline was available for 2,532 patients.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2532"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.66" lower_limit="0.0" upper_limit="6500.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidemiological Data: Tumor Staging (Positive or Negative) Via a Rectal Examination, Prostate Biopsy, Echograph, or Magnetic Resonance Imaging (MRI) Test.</title>
        <description>The number of participants at baseline who were positive or negative for tumors via a rectal examination, prostate biopsy, echograph of the hyperechogenic zones, or MRI are provided.</description>
        <time_frame>at time 0 (Baseline)</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants - Rectal Examination</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines who had tumor staging assessed via rectal examination.</description>
          </group>
          <group group_id="O2">
            <title>Advanced Prostate Cancer Participants - Prostate Biopsy</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines who had tumor staging assessed via a prostate biopsy.</description>
          </group>
          <group group_id="O3">
            <title>Advanced Prostate Cancer Participants - Echograph</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines who had tumor staging assessed via an echograph (hyperechogenic zones).</description>
          </group>
          <group group_id="O4">
            <title>Advanced Prostate Cancer Participants - MRI</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines who had tumor staging assessed via MRI.</description>
          </group>
        </group_list>
        <measure>
          <title>Epidemiological Data: Tumor Staging (Positive or Negative) Via a Rectal Examination, Prostate Biopsy, Echograph, or Magnetic Resonance Imaging (MRI) Test.</title>
          <description>The number of participants at baseline who were positive or negative for tumors via a rectal examination, prostate biopsy, echograph of the hyperechogenic zones, or MRI are provided.</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2484"/>
                <count group_id="O2" value="2364"/>
                <count group_id="O3" value="2252"/>
                <count group_id="O4" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2045"/>
                    <measurement group_id="O2" value="2355"/>
                    <measurement group_id="O3" value="1806"/>
                    <measurement group_id="O4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="446"/>
                    <measurement group_id="O4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidemiological Data: the Number of Participants With Tumor Stages T0, T1, T2, T3, and T4.</title>
        <description>The number of participants with tumor stages T0, T1, T2, T3, and T4 as reported by the physician or pathologist is summarized. T0: no evidence of primary tumor. T1: histologic tumor confined to prostate; clinically unapparent tumor, undetectable by digital rectal examination or by ultrasound. T2: tumor is confined to prostrate and can be detected by digital rectal examination. T3: tumor extends through the prostate capsule but has not spread to other organs. T4: tumor has invaded adjacent structures/organs other than seminal vesicles.</description>
        <time_frame>at time 0 (Baseline)</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Epidemiological Data: the Number of Participants With Tumor Stages T0, T1, T2, T3, and T4.</title>
          <description>The number of participants with tumor stages T0, T1, T2, T3, and T4 as reported by the physician or pathologist is summarized. T0: no evidence of primary tumor. T1: histologic tumor confined to prostate; clinically unapparent tumor, undetectable by digital rectal examination or by ultrasound. T2: tumor is confined to prostrate and can be detected by digital rectal examination. T3: tumor extends through the prostate capsule but has not spread to other organs. T4: tumor has invaded adjacent structures/organs other than seminal vesicles.</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T0 stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1 stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2 stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3 stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T4 stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidemiological Data: Node Staging - the Number of Participants With a Positive or Negative Computerized Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) Test</title>
        <description>In this case, a CT or MRI is considered positive when lymph nodes are detectable. A CT or MRI is considered negative when lymph nodes are not detectable.</description>
        <time_frame>at time 0 (Baseline)</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Epidemiological Data: Node Staging - the Number of Participants With a Positive or Negative Computerized Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) Test</title>
          <description>In this case, a CT or MRI is considered positive when lymph nodes are detectable. A CT or MRI is considered negative when lymph nodes are not detectable.</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1586"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidemiological Data: Node Staging - the Number of Participants With a N0 or N1 Stage at Baseline.</title>
        <description>N0: tumor cells absent from regional lymph nodes. N1: regional lymph node metastasis present.</description>
        <time_frame>at time 0 (Baseline)</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Epidemiological Data: Node Staging - the Number of Participants With a N0 or N1 Stage at Baseline.</title>
          <description>N0: tumor cells absent from regional lymph nodes. N1: regional lymph node metastasis present.</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1656"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>N0 stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1 stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidemiological Data: Bone Scan at Baseline</title>
        <description>The number of participants at baseline with a positive or negative bone scan was summarized. Determination of bone scan status was based on the interpretation of the Investigator or radiologist.</description>
        <time_frame>at time 0 (Baseline)</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Epidemiological Data: Bone Scan at Baseline</title>
          <description>The number of participants at baseline with a positive or negative bone scan was summarized. Determination of bone scan status was based on the interpretation of the Investigator or radiologist.</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1850"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epidemiological Data: Metastasis Staging (M0 or M1) at Baseline</title>
        <description>The number of participants at baseline reported to be in metastasis stage M0 or M1 is summarized. M0: no distant metastasis. M1: metastasis to distant organs beyond regional lymph nodes.</description>
        <time_frame>at time 0 (Baseline)</time_frame>
        <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Advanced Prostate Cancer Participants</title>
            <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
          </group>
        </group_list>
        <measure>
          <title>Epidemiological Data: Metastasis Staging (M0 or M1) at Baseline</title>
          <description>The number of participants at baseline reported to be in metastasis stage M0 or M1 is summarized. M0: no distant metastasis. M1: metastasis to distant organs beyond regional lymph nodes.</description>
          <population>Analysis was performed on the full analysis set (all patients for whom at least baseline data were recorded) and all available data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1874"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M0 stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1 stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events that occurred during the course of the study were reported and followed to a satisfactory conclusion.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Advanced Prostate Cancer Participants</title>
          <description>Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment with local reimbursement guidelines. No Baseline data was available for 3 patients who were thus excluded from all analyses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Terminal state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Therapeutic response decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Diet refusal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Breast cancer male</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Metastases to bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Ureteral neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bladder catheterisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Cardiac operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Porphyria non-acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2714"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

